Management of Tubercular Drug-Induced Hepatitis

Immediate Actions When Hepatotoxicity Occurs

The American Thoracic Society recommends stopping all hepatotoxic TB drugs immediately when liver enzymes rise to ≥5 times the upper limit of normal without symptoms, or ≥3 times the upper limit of normal with hepatitis symptoms 1, 2, 4
The Infectious Diseases Society of America suggests excluding other causes of liver injury before attributing hepatotoxicity to TB drugs, including testing for viral hepatitis and biliary tract disease 1, 4
The Centers for Disease Control and Prevention recommend continuing treatment with non-hepatotoxic drugs if the patient is acutely ill or has infectious TB, using ethambutol and an injectable agent or a fluoroquinolone 2, 3, 4

The British Thoracic Society advises reintroducing drugs one at a time with daily clinical and biochemical monitoring once liver function returns to less than 2 times the upper limit of normal and symptoms resolve 2, 4
The World Health Organization recommends starting with isoniazid at 50 mg/day, increasing to 300 mg/day after 2-3 days if no reaction occurs, then continuing 4
The American College of Chest Physicians suggests adding rifampin after 2-3 additional days without reaction, beginning at 75 mg/day and increasing to full dose after 2-3 days 2, 4

The European Respiratory Society recommends using isoniazid, rifampin, and ethambutol for 2 months, followed by 7 months of isoniazid and rifampin if pyrazinamide is identified as the culprit and cannot be reintroduced 5
The Infectious Diseases Society of America suggests treating with rifampin and ethambutol plus a fluoroquinolone, injectable agent, or cycloserine for 12-18 months depending on disease extent if both isoniazid and pyrazinamide cannot be used 5

The American Thoracic Society recommends checking baseline liver function tests in all patients before treatment initiation 1, 4
The Centers for Disease Control and Prevention suggest assessing for risk factors, including chronic liver disease, hepatitis B/C, HIV infection, and chronic alcohol use 4
The British Thoracic Society advises monitoring liver function tests and clinical symptoms daily during the reintroduction process 2, 4

The World Health Organization recommends patient education on symptoms of hepatitis and the importance of immediate reporting 4
The American College of Chest Physicians suggests that HIV-infected patients with CD4 <100/μL require daily or three-times-weekly therapy, never once-weekly regimens due to high relapse rates and acquired resistance 2
The Infectious Diseases Society of America advises against reintroducing pyrazinamide if it caused severe hepatotoxicity, as recurrence carries a poor prognosis 5